Study of risk factors for gastrointestinal bleeding and of the determinants of non-fatal and fatal cardiovascular events after gastrointestinal bleeding in patients receiving antithrombotic therapy for cardiovascular prevention
Antithrombotic therapies are effective for prevention of cardiovascular (CV) events but cause bleeding. Emerging evidence indicates that extra-cranial bleeding is just as important as myocardial infarction as a marker of risk for subsequent non-fatal and fatal CV events, but this issue has not been prospectively studied. If the association between bleeding and CV events is causal, prevention of bleeding, by targeting the risk factors, and prevention of the complications of bleeding, by targeting the causal pathways, could substantially reduce the burden of bleeding-related CV events.
Multicenter, two component observational study: standardized case-control study and prospective study
Composite of MI, stroke and death
Dr. John Eikelboom, Dr. Jackie Bosch
Heart and Stroke Foundation, Bristol-Myers Squibb, Daiichi Sankyo